Migraine Minute News Update

Association of Migraine Disorders
Migraine Minute News Update

The Migraine Minute provides weekly updates in migraine research and news hosted by Molly O'Brien of the Association of Migraine Disorders.

  1. 21H AGO · VIDEO

    FDA Approves Two New DHE Migraine Treatments for Fast Relief

    Two innovative DHE-based migraine treatments just earned FDA approval—offering some Americans new options for managing attacks. Molly O’Brien has details in this #MigraineMinute News Update. Read More: https://bit.ly/4kgmXMt and https://bit.ly/3SYet0c *DHE is not safe for the management of hemiplegic migraine, migraine with brainstem aura, in people with certain comorbidities, or in those who take certain medications. Script: Many Americans with migraine now have two new treatment options, thanks to recent FDA approvals of Brekiya and Atzumi. Both drugs utilize Dihydroergotamine or DHE. While DHE for migraine has been around for decades, these two new drugs have new delivery methods. Brekiya is the first and only DHE auto-injector approved for the acute treatment of migraine and cluster headache in adults.  Atzumi is the first and only DHE nasal powder approved for the acute treatment of migraine with or without aura in adults. It’s important to note that DHE has several safety implications and contraindications and must be prescribed by a healthcare provider.

    1 min

  2. JUL 4

    Navigating the 4th of July with Migraine: Triggers & Tips

    Celebrating the Fourth of July with migraine is not easy. The holiday can be packed with sensory overload and migraine triggers. In this Migraine Minute, Molly O’Brien shares tips to help you enjoy the celebration while protecting your health. Check out our updated triggers webpage: https://bit.ly/4kFOZRf Reference: https://pubmed.ncbi.nlm.nih.gov/19329386/ Script: While the Fourth of July can be a fun holiday to celebrate in the States, it can be tough for folks with migraine. Why? Well, there are so many factors that can be stacked against you. Think about it, heat, big crowds, staying up late, BBQ foods and drinks that might have triggering ingredients…Not to mention the bright flashes and loud bangs of fireworks. Research even shows exposure to sulfur dioxide, a common byproduct of fireworks, may trigger migraine attacks. If you have migraine and still want to enjoy the holiday, here are some tips from our migraine community: Stay hydrated, wear ear plugs, watch fireworks from afar or skip all together, bring migraine safe food and drinks to your cook out, wear sunglasses or migraine glasses, and keep a consistent routine. Don’t forget to check out AMD’s updated triggers page, where you can learn more about common migraine triggers and how to manage them.

    1 min

  3. JUN 6 · VIDEO

    Does PACAP 38 Work Differently Than CGRP?

    New research shows CGRP monoclonal antibody treatment may not prevent migraine attacks triggered by the neuropeptide PACAP-38. This study suggests PACAP-38 may act through a different pathway and could become a future preventive option for people who don’t respond to CGRP-based treatments. Molly O’Brien explains in this Migraine Minute News Update.  Read More: https://bit.ly/4ivy3LG Images courtesy: Springer Nature. The Journal of Headache and Pain. doi: 10.1186/s10194-025-02022-2 Creative Commons license: https://creativecommons.org/licenses/by-nc-nd/4.0/ Script: Does PACAP 38 Work Differently Than CGRP? A new study published in the Journal of Headache and Pain found that migraine attacks can be triggered by the neuropeptide PACAP-38 despite pre-treatment with a CGRP monoclonal antibody. Researchers gave 38 participants with migraine an infusion of eptinezumab—a CGRP monoclonal antibody—or placebo, followed by PACAP-38. The results showed no difference in the incidence of migraine attacks between the two groups. This study suggests that PACAP-38 may trigger migraine attacks through a different pathway than CGRP. Treatments targeting PACAP-38 may offer a new preventive option for people who’ve had limited or no success with CGRP monoclonal antibodies.

    1 min

  4. MAY 23 · VIDEO

    Can Erenumab Treat Medication Overuse Headache?

    A study published in JAMA Neurology shows that monthly erenumab injections may help treat medication overuse headache (MOH) in people with chronic migraine. While the 140 mg dose was effective for treating MOH, the 70 mg dose did not show a meaningful difference compared to placebo. Molly O’Brien explains in this Migraine Minute News Update. Read More: https://bit.ly/4jCusxk Image Courtesy: JAMA Neurology doi:10.1001/jamaneurol.2024.3043 Transcript: A study published in JAMA Neurology looked at the safety and efficacy of a CGRP monoclonal antibody for treating Medication Overuse Headache in people with chronic migraine. Results show that erenumab– sold under brand name Aimovig- can lead to lasting remission of MOH, reduce the need for pain medication, and improve daily functioning over six months. The study included 584 people with chronic migraine who also had medication overuse headache. At 6 months, 69.1% of those who received 140 mg injections of erenumab monthly no longer met the criteria for medication overuse headache compared to 52.6% of people in the placebo group. It should be noted that the study did not include people who had medication-overuse headache from opioid use.

    1 min

  5. MAY 9 · VIDEO

    Predicting if a Preventive Migraine Treatment Will Work

    Most people with migraine go through trial and error to find a preventive treatment that works. But researchers at the Mayo Clinic may have found a way to change that. Using AI, they developed a tool to predict how someone might respond to certain migraine medications—particularly CGRP monoclonal antibodies. Molly O’Brien has more in this Migraine Minute News Update. Read More: https://bit.ly/40uKyjE

    1 min

  6. APR 25 · VIDEO

    Can This Preventive Drug Bring Immediate Migraine Relief?

    Rapid relief from a preventive migraine treatment? A study published in Neurology shows that one oral gepant medication may start working right away to prevent migraine attacks. Molly O’Brien fills you in, in this Migraine Minute News Update. Read more: https://bit.ly/3Wvb1fU

    1 min

  7. APR 11 · VIDEO

    FDA Approves Axsome’s New Migraine Drug Symbravo®

    The FDA has approved a new drug for the acute treatment of migraine with or without aura in adults. Molly O’Brien has the details and when it becomes available in this Migraine Minute News update.    Learn More: https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-fda-approval-symbravor-meloxicam

    1 min

  8. MAR 28 · VIDEO

    Can CGRP Blocking Drugs Help Endometriosis?

    Researchers in Boston found that CGRP-blocking drugs commonly used for migraine may help with endometriosis pain and lesion size. Molly O’Brien has the details in this Migraine Minute news update recognizing Endometriosis Awareness Month.  Read More: https://bit.ly/4jp0cG2 AMD Comorbidities Library: https://bit.ly/3CIrLtd

    1 min
See All (95)

Ratings & Reviews

5
out of 5
5 Ratings

About

The Migraine Minute provides weekly updates in migraine research and news hosted by Molly O'Brien of the Association of Migraine Disorders.

Information

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada